Limfoblok

2021: Start of production in the SEZ "Dubna"

In mid-November 2021, it was announced the start of production in the Dubna SEZ of the drug Lymphoblock to stop bleeding. This is a project of the Pul-sar company, which has invested about 16 million rubles in it.

According to the developers, the product has a dense matrix structure that allows you to effectively seal the internal micro-cavities and quickly restore the damaged fabric. Its use, the manufacturer is believed to allow three times reducing the stay of patients with oncology in the hospital after surgical operations.

Production of hemostatics to stop bleeding for ₽16 million began in the Dubna SEZ

The ability of blood to clot prevents blood loss, and this is due to the balance of the clotting and anti-coagulation system. However, in some cases, the human body cannot cope, and then hemostatic drugs come to its aid. "Lymphoblock" will primarily be used in surgical operations.

The project of the company "Pul-sar" is aimed at localization and development of medical devices for surgery, including the production of products for stopping bleeding. On the territory of the SEZ in Dubna, the resident is already releasing the Hemoblock tool of his own development. A liquid hemostatic having a hemostatic effect has no analogues in the world, and the peculiarity of the action is that it is chemically neutral and does not damage the body tissues. This drug occupies a significant share of the market for hemostatic products of the Russian Federation and is exported to many European and Asian countries.

Lymphoblock is the only drug in the world to block lymph bleeding during operations to remove lymph nodes, "said Ksenia Menglet, general director of Pul-sar LLC.

By mid-November 2021, the drug began to be supplied to domestic cancer hospitals and clinics.^[1]

Notes